Our thesis
B2B healthcare companies from outside the US with external clinical and technical validation, ready to enter the US within six months. Interests include cardiology, diagnostics, oncology, and women’s health.
Venture Atlas Labs Capital Syndicate
A network of US corporate venture funds and innovation departments that appreciate the value of EU and ANZ healthtech and life science companies—and bring more than a checkbook.
Let’s talkThe perspective
Strong companies. Aligned capital.
One of the biggest hurdles in crossing borders is operating capital. That takes a certain kind of investor—one who can ideally contribute additional commercial resources. After working with corporate leaders and sales teams for years in imaging, cardiology, and diagnostics, we created a structured process to syndicate deals that complement their US portfolio and offer meaningful “wind in the sails” for our international scaleups.
Our sweet spot
$3.5–5M USD, with recommended networks and funds for rounds above and below this range. Open to most vehicles with reasonable terms at grounded valuations.
The process
Rolling applications, a team interview, down-selection, investor syndication, and due diligence concluding in a deal memo. Interviews are generally scheduled within three weeks.
Application & feedback
Like many syndicates and networks, there’s a $150 application fee, which includes specific feedback. We aren’t brokers, however, and are very transparent about the process.
The next step
Let’s see if there’s a fit.
Reach out with your pitch or ask about joining the investment network.
Start a conversation